March 13, 2019
Mitsubishi Tanabe Pharma’s hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat (MT-6548) demonstrated favorable efficacy and safety in four PIII studies in Japan in renal anemia patients, according to the topline results announced by the company on March 12. Mitsubishi Tanabe...read more